---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114279"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T21:59:51.462640+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell receives Nasdaq bid price deficiency notice; has until April 29, 2024 to comply

## Summary
- Nasdaq notified BCLI on Nov 1, 2023 of non-compliance with $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).
- No immediate delisting; stock continues trading on Nasdaq Capital Market under symbol BCLI.
- Company has 180 days, until April 29, 2024, to regain compliance by closing at or above $1.00 for 10 consecutive business days.
- If not compliant by April 29, BCLI may qualify for an additional 180-day compliance period if other listing standards are met.
- Company intends to monitor bid price and take reasonable measures, but there is no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001104659-23-114279
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923114279/0001104659-23-114279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923114279/tm2329650d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114279
- JSON: https://secwatch.observer/filing/0001104659-23-114279.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114279.txt

## Key facts
- Listing & Compliance Notices
  BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)
  source text: November 1, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923114279/0001104659-23-114279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.